BPC-157 vs KPV
Both are anti-inflammatory, repair-adjacent peptides referenced in gut-focused research literature, and both appear together in our KLOW Blend — but they come from entirely different parent molecules and act through different mechanisms.
At a Glance
| BPC-157 | KPV | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Molecular class | Pentadecapeptide (15 amino acids), derived from a gastric protective protein | Tripeptide (3 amino acids), the minimal active fragment of alpha-MSH(11-13) |
| Discovery timeline | 1975–1993, University of Zagreb | Characterized by Anna Catania and James Lipton's research group at Weill Cornell |
| Primary mechanism studied | Cytoprotection, angiogenesis | Anti-inflammatory activity, independent of the melanocortin receptor's pigmentation effects |
| Common research focus | Gastrointestinal and musculoskeletal repair research | Cytokine signaling and gut-inflammation models |
| Human clinical trial data | None completed — evidence limited to animal and in-vitro research | None completed — evidence limited to animal and in-vitro research |
| Sold as a blend | Yes — see KLOW Blend | Yes — see KLOW Blend |
How They Differ
BPC-157's research lineage traces to cytoprotection — the stomach's own ability to resist injury and self-digestion — and its research applications have grown outward into gastrointestinal repair, angiogenesis, and musculoskeletal healing research. See its full discovery history, or how it compares to TB-500.
KPV's lineage is different: it's the minimal active fragment of alpha-MSH, a hormone best known for its role in pigmentation. Researchers found that KPV retains alpha-MSH's anti-inflammatory activity while showing no pigmentation effect, which redirected its research focus toward cytokine signaling and gut-inflammation models specifically. See its full discovery history, or how it compares to GHK-Cu.
Why They're Often Studied Together
Because BPC-157's cytoprotective/angiogenic repair mechanism and KPV's anti-inflammatory cytokine modulation act on different parts of the gut-repair process, researchers studying regenerative and anti-inflammatory pathways together often reference both compounds — the same rationale behind combining them, alongside TB-500 and GHK-Cu, in the KLOW Blend.
BPC-157 vs KPV questions
Are BPC-157 and KPV studied for the same thing?
Not exactly. BPC-157's research base centers on cytoprotection and angiogenesis in gastrointestinal and musculoskeletal repair. KPV's research base centers on anti-inflammatory activity tied to cytokine signaling, with a particular focus on gut-inflammation models. Both are relevant to gut-repair research, which is part of why they're combined in the KLOW Blend.
Have BPC-157 and KPV completed human clinical trials?
No. Neither has completed a human clinical trial. Both have evidence limited to animal and in-vitro research.
Does this comparison mean BPC-157 and KPV are approved for a particular use?
No. This page compares BPC-157 and KPV for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.